ReviewFrontiers in oncology2018
Role of Epstein-Barr Virus in the Pathogenesis of Head and Neck Cancers and Its Potential as an Immunotherapeutic Target.
Review in Frontiers in oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 56 citations in OpenAlex.
- The triad of nasopharyngeal carcinoma pathogenesis: host genetics, viral infection, and environmental exposures.Frontiers in oncology · 2026Review
- Radiation therapy response prediction for head and neck cancer using multimodal imaging and multiview dynamic graph autoencoder feature selection.Medical physics · 2025Article
- Article
- The CRISPR-Cas revolution in head and neck cancer: a new era of targeted therapy.Functional & integrative genomics · 2025Review
- Current nano drug delivery systems for targeting head and neck squamous cell carcinoma microenvironment: a narrative review.Molecular biology reports · 2025Review
- Identification of B cell antigens in solid cancer: initial insights and functional implications.Frontiers in immunology · 2025Review
- Hybrid-Capture Target Enrichment in Human Pathogens: Identification, Evolution, Biosurveillance, and Genomic Epidemiology.Pathogens (Basel, Switzerland) · 2024Review
- Influence of pathogens on host genome and epigenome in development of head and neck cancer.Cancer reports (Hoboken, N.J.) · 2023Review
- Incidence and association of high-risk HPVs and EBV in patients with advanced stages of colorectal cancer from Qatar.Human vaccines & immunotherapeutics · 2023Article
- The Clinical Characteristics and Outcomes of Human Papillomavirus-Positive Nasopharyngeal Carcinoma in a Single-Institution Cohort.Journal of clinical medicine · 2023Article
- A Survey of Human Papillomavirus and Epstein-Barr virus Immunohistochemical Status in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC).Head and neck pathology · 2023Article
- Artificial intelligence to predict outcomes of head and neck radiotherapy.Clinical and translational radiation oncology · 2023Article
- Identification of hub genes involved in cisplatin resistance in head and neck cancer.Journal, genetic engineering & biotechnology · 2023Article
- LMP1-EBV Gene Deletion Mutations and HLA Genotypes of Nasopharyngeal Cancer Patients in Vietnam.Pathophysiology : the official journal of the International Society for Pathophysiology · 2023Article
- Review
- Article
- Carcinomatous-like mastitis due to axillary lymphadenopathy in a case of nasopharyngeal carcinoma: A case report.Experimental and therapeutic medicine · 2021Article
- Epstein-Barr Virus Latent Membrane Protein-1 Expression in Nasopharyngeal Carcinoma.JCO global oncology · 2021Article
- Molecular Genetics in Epstein-Barr Virus-Associated Malignancies.Life (Basel, Switzerland) · 2021Review
- Meet the Insidious Players: Review of Viral Infections in Head and Neck Cancer Etiology with an Update on Clinical Trials.Microorganisms · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of Epstein-Barr virus (EBV) infection in the development and progression of tumor cells has been described in various cancers. Etiologically, EBV is a causative agent in certain variants of head and neck cancers such as nasopharyngeal cancer. Proteins expressed by the EVB genome are involved in invoking and perpetuating the oncogenic properties of the virus. However, these protein products were also identified as important targets for therapeutic research in the past decades, particularly within the context of immunotherapy. The adoptive transfer of EBV-targeted T-cells as well as the development of EBV vaccines has opened newer lines of research to conceptualize novel therapeutic approaches toward the disease. This review addresses the most important aspects of the association of EBV with head and neck cancers from an immunological perspective. It also aims to highlight the current and future prospects of enhanced EBV-targeted immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.